BioSpace News Archive

Taiho Oncology, Inc. announced results of a U.S. real-world study of oral decitabine and cedazuridine in patients with myelodysplastic syndromes, a rare form of blood cancer.

Regeneron Pharmaceuticals, Inc. announced positive data for odronextamab in patients with relapsed/refractory follicular lymphoma from a pivotal Phase 2 trial.

Novartis announced results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta® in adults with paroxysmal nocturnal hemoglobinuria who had residual anemia despite previous anti-C5 therapy.

MorphoSys AG announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

Positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® or SOLIRIS® continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock at a price of $0.63 per share.

NovalGen Ltd, a pioneering clinical stage immunology company, shared promising findings from the NVG-111-101, a First in Human, Phase I clinical study, in an oral presentation at the 65th American Society of Hematology Annual meeting, in San Diego, USA.

Jasper Therapeutics, Inc. announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia in complete remission or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplant.

Centessa Pharmaceuticals plc, announced new data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia.

Chroma Medicine, Inc. presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor T cells at the American Society of Hematology 65th Annual Meeting in San Diego.